Work

A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.612

Authors: Pavlos Msaouel, Peter F. Thall, Ying Yuan, Xuemei Wang, Eric Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Hirak Der-Torossian, Nizar M. Tannir

Institutions: The University of Texas MD Anderson Cancer Center, Mirati Therapeutics (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Mirati Therapeutics

OpenAlex ID: W3008933571

Cites:

Cited by: 9

Related to: 10